ArticleParasites & vectors2026
Assessing the susceptibility of 200 Rhipicephalus microplus populations to fluralaner using larval immersion test: A nationwide analysis from Brazil.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundIn 2022, a tick control product, against Rhipicephalus microplus, containing fluralaner as the active ingredient was initially launched in the Brazilian market, followed by other markets across Latin America. Once a new molecule is introduced for the control of a parasitic organism, it becomes essential to develop methods for assessing the susceptibility of target parasitic populations. In this context, discriminating dose (DD) tests represent a valuable tool.
methodsThis study evaluated the susceptibility profile of 200 R. microplus populations originating from 21 federal units (20 states and a federal district) across all five regions of Brazil, using a larval immersion test (LIT) with two discriminating doses (DD) of 1.55 and 3.16 µg/mL. Populations showing mortality rates above 95% were classified as susceptible. A field trial was also conducted with one population (São José do Rio Pardo [SJRP]), which had a known history of exposure to fluralaner, to compare laboratory and field test outcomes.
resultsThe DD at a concentration of 1.55 µg/mL resulted in 100% mortality in 160 populations (80%), whereas the DD at a concentration of 3.16 µg/mL showed more consistent results, with 100% mortality in 182 populations (91%). In the field trial population, SJRP, fluralaner achieved 100% therapeutic efficacy (days +7 to +21) and persistent efficacy (days +28 to +42).
conclusionsLIT using DDs can provide indicative data on the susceptibility of R. microplus to fluralaner. The discriminating dose at a concentration of 3.16 µg/mL was shown to be the most appropriate for monitoring the susceptibility of R. microplus populations to fluralaner. Laboratory and field data support the classification of the SJRP population as susceptible, demonstrating consistency between the two sets of results. These results can serve as a basis for continuous spatial and temporal monitoring of the susceptibility of R. microplus populations to fluralaner. Continued research, integrating laboratory and field results, is essential to increase the reliability of laboratory-based testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.